The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
30
Administered subcutaneously (SC)
Administered orally
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Pharmacokinetics (PK): Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol
PK: AUC (0-∞) of Metoprolol
Time frame: Day 1 to Day 3
Pharmacokinetics (PK): AUC (0-∞) of Metoprolol with Retatrutide
PK: AUC (0-∞) of Metoprolol with Retatrutide
Time frame: Day 9 to Day 11
PK: Maximum Concentration (Cmax) of Metoprolol
PK: Cmax of Metoprolol
Time frame: Day 1 to Day 3
PK: Cmax of Metoprolol with Retatrutide
PK: Cmax of Metoprolol with Retatrutide
Time frame: Day 9 to Day 11
Number of Participants with an Incidence of Treatment Emergent Adverse Events TEAEs (TEAEs)
Time frame: Baseline to Day 44
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.